PH-905 / Phio Pharma - LARVOL DELTA

Phio Announces Data Showcasing INTASYL’s Role in Helping Immune Cells Target and Kill Cancer Cells (Phio Pharma Press Release) - "Phio Pharmaceuticals Corp....today announced that it is presenting data about its proprietary INTASYL platform and INTASYL compounds....INTASYL compound PH-762 silences PD-1, improving therapeutic efficacy in vivo. The PH-894 compound precisely silences BRD4 to enhance tumor cell immunogenicity and induce apoptosis. Silencing TIGIT in NK cells, using compound PH-804, enhances their activation, cytokine release, and target cell killing. The PH-905 compound silences CBLB, increasing NK cell cytotoxicity and proliferation....The data is being presented on October 8th at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal."

Preclinical • Oncology

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (Phio Pharma Press Release) - "Phio Pharmaceuticals Corp...announced it is presenting new data about INTASYL on March 21st. The event is scheduled to take place at the 10th Immunotherapy of Cancer Conference (ITOC10), which will be held in Munich, Germany from March 21-23, 2024....The preclinical data demonstrate the following: INTASYL self-delivering RNAi compound PH-905 effectively targets and silences Cbl-b in primary NK cells without negative impact on their viability. Silencing of Cbl-b results in increased proliferation of primary NK cells. INTASYL silencing of Cbl-b in primary NK cells enhanced their functional cytotoxicity towards tumor cells. Silencing of Cbl-b leads to enhanced fitness of NK cells through increased expression of CD98 and CD25, potentially improving NK metabolism and promoting activation in response to IL-2."

Preclinical • Hematological Malignancies • Oncology

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire) - "Phio Pharmaceuticals Corp...announced that new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b improves natural killer (NK) cell activity for adoptive cell therapy and may result in a more effective cell therapy for hematological malignancies will be presented at the 10th Immunotherapy of Cancer Conference (ITOC10), which will be held in Munich, Germany from March 21-23, 2024."

Preclinical • Hematological Malignancies • Oncology